Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo to Present at Sidoti Virtual Conference

Wednesday, June 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. will present at the Sidoti Virtual Investor Conference on June 12-13, 2024. CEO Paul Gudonis and CFO David Henry will lead the presentation and host one-on-one meetings with investors. This engagement aims to enhance investor relations and showcase Myomo's advancements in wearable medical robotics.
Price reaction · baseline $3.4445 (2024-06-05T17:56:00.000Z) · hit during market hours · clean, no other MYO news in the window
day 0 close · peak
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Myomo is actively engaging with investors.
  • The presentation may enhance visibility for the company.
  • The conference provides a platform for networking and discussions.

Full Press Release Details

BOSTON (June 5, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024. Read more .

Frequently Asked Questions

When is Myomo presenting at the Sidoti Conference?

Myomo will present at the Sidoti Virtual Investor Conference on June 12-13, 2024.

Who will represent Myomo at the conference?

Paul Gudonis, CEO, and David Henry, CFO, will represent Myomo.

What is the focus of Myomo's presentation?

The presentation will focus on Myomo's advancements in wearable medical robotics.

What opportunities will be available at the conference?

The conference will include one-on-one meetings with investors.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo Sidoti Conference investor presentation wearable robotics neurological disorders
Last updated: Jun 5, 2024

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~20 mo
Low dilution risk